is being presented by Kelly Savage Day, Senior Associate, with Sedgwick LLP and airs on Wednesday, October 26th, 2011. For more details or to register, please visit our site at www.fxconferences.com
In this brave new world of Twitter, Facebook, LinkedIn and other social media websites, risk and opportunity may be combined. There is no question that social networking represents the emergence of a tremendous marketing and customer education opportunity, but there are also pitfalls for the FDA-regulated company. What happens if you go too far, say too much? Do you need to be concerned about the use of these networking sites by employees?
This audio conference presentation tackles some of the important issues that social media poses for life science companies – the benefits, risks, and mitigating that risk – and provides insight on how to use social media to positively impact your business, without running afoul of regulators.
Showing posts with label Kelly Savage Day. Show all posts
Showing posts with label Kelly Savage Day. Show all posts
Tuesday, September 27, 2011
Monday, August 8, 2011
Jagged Little Pill: Are Innovators Liable for Generic Drug Manufacturers' Failure to Warn?
is being presented by Kelly Savage Day & Mike Healy, Senior Associate & Partner, with Sedgwick LLP an airs on Tuesday, August 30th, 2011. For more details or to register, please visit our site at www.fxconferences.com
The Supreme Court recently held that federal labeling laws preempt state failure-to-warn claims brought against manufacturers of generic drugs. While the 5-4 decision marks a significant win for generic companies, many innovators are concerned that the Court’s ruling may adversely affect their business by making it more likely that other courts will adopt the holding set forth in California’s Conte v. Wyeth decision. Under Conte, brand-name manufacturers may be liable for injuries suffered by those plaintiffs who take a generic version of their brand-name drug.
This audio conference examines the potential legal risks innovators face, and offers concrete suggestions for proactively mitigating these risks. The presentation focuses on the current status of the law concerning innovator-generic liability, featuring speakers with first-hand experience in this litigation and the industry-shaking issues it raises.
The Supreme Court recently held that federal labeling laws preempt state failure-to-warn claims brought against manufacturers of generic drugs. While the 5-4 decision marks a significant win for generic companies, many innovators are concerned that the Court’s ruling may adversely affect their business by making it more likely that other courts will adopt the holding set forth in California’s Conte v. Wyeth decision. Under Conte, brand-name manufacturers may be liable for injuries suffered by those plaintiffs who take a generic version of their brand-name drug.
This audio conference examines the potential legal risks innovators face, and offers concrete suggestions for proactively mitigating these risks. The presentation focuses on the current status of the law concerning innovator-generic liability, featuring speakers with first-hand experience in this litigation and the industry-shaking issues it raises.
Tuesday, March 1, 2011
The FDA and Social Media
is being presented by Kelly Savage Day, Senior Associate, with Sedgwick, Detert, Moran & Arnold LLP and airs on Thursday, March 31st, 2011. For more details or to register for this event, please visit our site at www.fxconferences.com
In this brave new world of Twitter, Facebook, LinkedIn and other social media websites, risk and opportunity may be combined. There is no question that social networking represents the emergence of a tremendous marketing and customer education opportunity, but there are also pitfalls for the FDA-regulated company. What happens if you go too far, say too much? Do you need to be concerned about the use of these networking sites by employees?
This audio conference presentation tackles some of the important issues that social media poses for life science companies – the benefits, risks, and mitigating that risk – and provides insight on how to use social media to positively impact your business, without running afoul of regulators.
In this brave new world of Twitter, Facebook, LinkedIn and other social media websites, risk and opportunity may be combined. There is no question that social networking represents the emergence of a tremendous marketing and customer education opportunity, but there are also pitfalls for the FDA-regulated company. What happens if you go too far, say too much? Do you need to be concerned about the use of these networking sites by employees?
This audio conference presentation tackles some of the important issues that social media poses for life science companies – the benefits, risks, and mitigating that risk – and provides insight on how to use social media to positively impact your business, without running afoul of regulators.
Subscribe to:
Posts (Atom)